Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer

Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer

Item
http://www.wikidata.org/entity/Q34613130
Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factorsMulticentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL StudyChemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequencesPatterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma.Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.
P2860

Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer

Item
http://www.wikidata.org/entity/Q34613130
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Development and validation of ...... olorectal, and prostate cancer
@ast
Development and validation of ...... olorectal, and prostate cancer
@en
Development and validation of ...... olorectal, and prostate cancer
@nl
type
label
Development and validation of ...... olorectal, and prostate cancer
@ast
Development and validation of ...... olorectal, and prostate cancer
@en
Development and validation of ...... olorectal, and prostate cancer
@nl
prefLabel
Development and validation of ...... olorectal, and prostate cancer
@ast
Development and validation of ...... olorectal, and prostate cancer
@en
Development and validation of ...... olorectal, and prostate cancer
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Development and validation of ...... olorectal, and prostate cancer
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932